Publications by authors named "U Ravens"
"Cardiac glycosides"-quo vaditis?-past, present, and future?
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Article Synopsis
- Digitalis glycosides, or cardiac glycosides, are drugs that inhibit the Na/K-ATPase and are commonly used to treat heart failure and atrial fibrillation.
- Despite their effectiveness, these drugs have a narrow therapeutic range, leading to debates about their necessity and safety in these conditions.
- The article aims to review the historical context, key research findings, and the overlooked advantages and disadvantages of using digitalis glycosides in clinical practice.
Macrophages (MΦ) play pivotal roles in tissue homeostasis and repair. Their mechanical environment has been identified as a key modulator of various cell functions, and MΦ mechanosensitivity is likely to be critical - in particular in a rhythmically contracting organ such as the heart. Cultured MΦ, differentiated in vitro from bone marrow (MΦ), form a popular research model.
View Article and Find Full Text PDFAims: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA).
Methods And Results: Eighty-three international experts met in Münster for 2 days in September 2023.
[Genetics in atrial fibrillation and malignant arrhythmia syndromes].
Herzschrittmacherther Elektrophysiol
March 2024